GLP-1 medications changed the direction of bariatric surgery volume. They didn't change the bigger fact underneath it: most people who could be treated for severe obesity still aren't treated at all.
For a bariatric practice, both halves of that matter. This post is about what the data actually shows, what it doesn't, and what it means for how a surgical practice markets itself now.
What changed
A UC San Diego team presented an analysis at the American Society for Metabolic and Bariatric Surgery's 2026 annual meeting. It looked at health records for patients with severe obesity, and without diabetes, from 2018 to 2025.
In that dataset, bariatric procedures rose from just under 20,000 in 2018 to almost 43,000 in 2023. Then, for the first time, they fell: to 37,339 in 2024 and 33,429 in 2025. Over the same years, GLP-1 prescriptions in the same population went from under 4,600 to more than 1.4 million.
That's a real change in direction, and it's worth being precise about what it is. It's one electronic health record dataset, limited to severe obesity without diabetes. ASMBS's own national estimate is more than 270,000 bariatric procedures in 2023, drawn from broader data. So this study shows the trend turning. It doesn't give you a national percentage, and I won't turn it into one.
Most eligible patients are still untreated
The more important number is the one that didn't move. In the same study, the share of people with severe obesity who received no obesity treatment at all stayed between 90% and 95%.
Read that next to the drop in procedures. The medications didn't take a fixed pool of surgical patients and empty it. Most of the people who could be treated weren't being treated before GLP-1, and they still aren't. The market didn't vanish. Most of it was never reached.
For a bariatric practice, that changes the question. It isn't "is there still demand for surgery?" It's "are we reaching the people who haven't been treated by anyone, and are we ready for the ones who arrive having already tried something else?"
The conversation has changed
When a patient contacts a bariatric practice now, they may have already looked at medication, tried it, or be weighing it against surgery. I won't make claims about which is right for whom. That's a clinical conversation, and it belongs to the surgeon.
What marketing can do is not pretend the question doesn't exist. A page that talks about surgery as if GLP-1 medications had never happened reads as out of date to a patient who's been reading about little else. The practice's pages, and its first reply to an inquiry, should be ready for "I've been thinking about the medication" without turning it into an argument.
This is also why the long decision cycle matters even more. A patient comparing options takes longer to decide, not less. Follow-up that stops after two weeks gives up on them right when they're working it out. I covered that in why the bariatric seminar stopped filling the room.
Keep surgical and medication marketing separate
Many practices now offer both: surgery, and a medical weight-loss or GLP-1 program. It's tempting to market them together. It's usually a mistake.
They're different service lines with different patients, decisions, rules and numbers. I run them as separate campaigns, bariatric separate from medical weight loss, so each budget answers to its own results. The bariatric program is built for one service line, a patient considering sleeve or bypass. Medication programs have their own constraints, mostly around advertising rules and speed, which I cover on medical weight loss marketing.
Within surgery there's a further split worth keeping: the insurance patient and the self-pay patient decide differently, which I went through in insurance and self-pay bariatric patients are two buyers.
What I won't claim
I won't tell you surgery volume is down by a particular percentage nationally. The study doesn't support that, and nor does anyone else's single dataset.
I won't make claims about how GLP-1 medications compare with surgery, about outcomes or weight regain. Those are clinical claims, outside what I do.
And I won't promise that GLP-1 is good or bad for your practice. It depends on your market, your case mix and how you reach the patients who haven't been treated yet.
What I will put in writing is a number: fifteen paying bariatric patients in ninety days through the bariatric program. If you miss it, you get the entire fee back and I keep working at no fee until you have fifteen, while the agreed ad budget is funded.
Bariatric and GLP-1 questions
Has GLP-1 reduced demand for bariatric surgery?
In one large health-record study presented at ASMBS 2026, bariatric procedures in patients with severe obesity and no diabetes rose to almost 43,000 in 2023, then fell to 37,339 in 2024 and 33,429 in 2025, while GLP-1 prescriptions rose sharply. It shows the direction changing in that dataset, not a national percentage.
Is there still a market for bariatric surgery?
In the same study, 90% to 95% of people with severe obesity received no obesity treatment at all, and that share didn't change. Most eligible patients were never being reached, before or after GLP-1.
Should a practice market surgery and GLP-1 programs together?
I'd keep them separate. They're different service lines with different patients, rules and numbers. Separate campaigns let each budget answer to its own results.
Will you make claims comparing surgery and medication?
No. Comparing treatments is a clinical conversation that belongs to the surgeon. Marketing's job is to make sure the patient gets a fast, real answer and a clear next step.